Table 2.
Change in AER in the various subgroups of patients
| Dapagliflozin | Comparators | |||||
|---|---|---|---|---|---|---|
| Subgroup | Baseline | Follow‐up | Change | Baseline | Follow‐up | Change |
| All patients, n | 273 | 273 | 273 | 1380 | 1380 | 1380 |
| Mean ± SEM | 105.0 ± 20.3 | 65.8 ± 10.4a | −39.3 ± 14.8b | 76.3 ± 6.6 | 70.4 ± 6.1 | −5.9 ± 4.1 |
| Median (IQR) | 19.5 (7.5; 78.1) | 13.2 (6.5; 45.0)a | −2.1 (−26.4; 2.3)b | 14.9 (7.2; 41.3) | 12.3 (7.0; 34.4) | −0.5 (−9.6; 4.3) |
| By baseline albuminuria | ||||||
| Normoalbuminuria, n | 164 | 164 | 164 | 951 | 951 | 951 |
| Mean ± SEM | 10.5 ± 0.6 | 13.3 ± 1.9 | 2.8 ± 1.8 | 10.6 ± 0.2 | 14.9 ± 1.1a | 4.3 ± 1.1 |
| Median (IQR) | 8.4 (5.5; 15.2) | 8.8 (4.8; 13.3) | 0.0 (−3.0; 2.7) | 8.9 (5.1; 15.3) | 8.8 (4.9; 51.3) | 0.0 (−3.0; 3.9) |
| Microalbuminuria, n | 93 | 93 | 93 | 356 | 356 | 356 |
| Mean ± SEM | 108.6 ± 7.0 | 84.7 ± 14.1 | −23.8 ± 13.6 | 90.6 ± 3.4 | 90.1 ± 7.8 | −0.5 ± 6.9 |
| Median (IQR) | 90.0 (52.1; 143.9) | 49.4 (21.6; 89.1)a | −35.3 (−75.9; −3.3)b | 66.7 (42.0; 121.2) | 43.5 (20.1; 93.4) | −17.7 (−46.7; 7.1) |
| Macroalbuminuria, n | 16 | 16 | 16 | 73 | 73 | 73 |
| Mean ± SEM | 1054.0 ± 243.6 | 493.1 ± 107.2a | −560.9 ± 204.0b | 861.5 ± 78.9 | 697.5 ± 76.4a | −164.0 ± 66.7 |
| Median (IQR) | 590.8 (480.2; 1228.5) | 379.1 (172.4; 661.7)a | −265.4 (−786.0; −113.2) | 630.6 (389.6; −1082.0) | 519.0 (318.0; −858.0)a | −184.5 (−343.5; −95.0) |
| By ACEi/ARBs therapy | ||||||
| No ACEi/ARBs, n | 68 | 68 | 68 | 345 | 345 | 345 |
| Mean ± SEM | 44.5 ± 9.4 | 24.5 ± 4.3a | −20.1 ± 7.4 | 47.5 ± 10.1 | 32.7 ± 4.4 | −14.7 ± 8.0 |
| Median (IQR) | 11.4 (6.5; 50.1) | 10.8 (6.0; 27.0)a | −1.5 (−8.1; 2.0) | 10.7 (6.8; 25.9) | 10.5 (6.4; 23.0) | −0.5 (−6.0; 3.0) |
| ACEi/ARBs, n | 179 | 179 | 179 | 872 | 872 | 872 |
| Mean ± SEM | 132.8 ± 30.2 | 83.5 ± 15.1a | −49.3 ± 22.4b | 96.4 ± 9.6 | 93.2 ± 9.4 | −3.2 ± 5.7 |
| Median (IQR) | 23.7 (8.5; 103.7) | 15.8 (8.1; 66.8)a | −3.0 (−31.9; 3.0)b | 16.9 (7.4; 56.5) | 13.4 (7.1; 45.1) | −0.7 (−12.4; 4.6) |
| By baseline eGFR | ||||||
| eGFR >90 mL/min/1.73 m2, n | 97 | 97 | 97 | 293 | 293 | 293 |
| Mean ± SEM | 136.5 ± 45.5 | 82.8 ± 23.8 | −53.7 ± 33.6 | 58.5 ± 9.1 | 49.6 ± 8.8 | −8.9 ± 8.0 |
| Median (IQR) | 19.0 (7.4; −75.0) | 12.0 (7.5; −48.8)a | −2.1 (−27.0; −2.7) | 15.2 (6.8; 47.3) | 12.0 (6.0; 32.4) | −1.0 (−12.3; 4.5) |
| eGFR ≤90 mL/min/1.73 m2, n | 92 | 92 | 92 | 566 | 566 | 566 |
| Mean ± SEM | 115.6 ± 34.3 | 69.2 ± 15.0 | −46.4 ± 25.6b | 96.9 ± 12.5 | 94.2 ± 12.3 | −2.8 ± 6.8 |
| Median (IQR) | 25.1 (8.1; −123.7) | 18.5 (7.1; −70.1)a | −2.7 (−30.7; −2.0)b | 15.8 (6.5; 48.9) | 13.0 (6.0; 39.2) | −0.7 (−10.6; 4.6) |
Values of AER are reported both as mean ± SEM (with p values from paired Student's t test) and as median and IQR (with P values from Wilcoxon rank test). ACEi, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers.
a
P < 0.05 versus baseline.
b
P < 0.05 versus comparators.